Health Condition 1: - Health Condition 2: F949- Childhood disorder of social functioning, unspecified
Conditions
Interventions
Intervention1: Vitamin D: Vitamin D capsule 800 IU will daily given to children for 6 months
Control Intervention1: Nil: Nil
Sponsors
BANBEIS Ministry of Education
Eligibility
Inclusion criteria
Inclusion criteria: ) Autistic children with 25(OH)D deficiency ( iv) Children having no significant hearing or vision loss. v) Children having no other neurological disorders, e.g., cerebral palsy, phenylketonuria, tuberous sclerosis, neurofibromatosis, and seizure disorders. vi) Children having no history of severe head trauma or stroke. vii) Children having no feeding problems or malnutrition. viii) Children having no genetic disorders (i.e., Down syndrome, fragile x, Rett syndrome). ix) Children having no Prematurity or postmaturity. x) Subjects are not associated with gastrointestinal problems, autoimmune disorders, and anemia. xi) Children with no known endocrine, cardiovascular, pulmonary, liver or kidney disease, clinically active infection, morbid obesity, cancer. xii) Participants at present or within the preceding 2 months before the study are not taking the following medications or supplements: cod liver oil, vitamin A, Vitamin D, minarels, steroids, thiazide diuretics, digoxin, diltiazem, verapamil, cimetidine, heparin. xii) Children having no relevant interaction of prescribed vitamin D with concurrent medication or contraindications. xiii) Children having no hypersensitivity reactions to vitamin D.
Exclusion criteria
Exclusion criteria: Age: below 2 years and above 15 years. ii) Children with normal serum 25(OH)D level (above 30 ng/ml). iii) Children having significant hearing or vision loss. iv) Children having other neurological disorders, e.g., cerebral palsy, phenylketonuria, tuberous sclerosis, neurofibromatosis, and seizure disorders. v) Children having history of severe head trauma or stroke. v) Children having feeding problems or malnutrition. vi) Children having genetic disorders (i.e., Down syndrome, fragile x, Rett syndrome). vii) Children having prematurity or post maturity. viii) Subjects are associated with gastrointestinal problems, autoimmune disorders, and anemia. ix) Children with known endocrine, cardiovascular, pulmonary, liver or kidney disease, clinically active infection, morbid obesity, cancer. x) Participants at present or within the preceding 2 months before the study are taking the following medications or supplements: cod liver oil, vitamin A, Vitamin D, minarels, steroids, thiazide diuretics, digoxin, diltiazem, verapamil, cimetidine, heparin. xi) Children having relevant interactions of prescribed vitamin D with concurrent medication or contraindications. xii) Children having hypersensitivity reactions to vitamin D.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parameters: 1. DSM 5 Diagnostic Criteria for ASD scores 2. Adverse event due to supplementation of Vitamin DTimepoint: Baseline (Day 0) to complete recovery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Increased serum vitamin levels (ng/ml) levels towards normalTimepoint: Day 0, 90, 180 | — |
Countries
Bangladesh
Contacts
Public ContactAbu Syed Md Mosaddek
Uttara Adhunik Medical College
Outcome results
None listed